GSK reports its long-acting HIV PrEP tops Gilead's Truvada — again
GSK subsidiary ViiV Healthcare is notching another win on its scorecard for cabotegravir, the long-acting injectable it hopes can supplant Gilead’s daily pill for HIV prevention.
The company reported back in July that a head-to-head study showed that cabotegravir is 66% more effective than Gilead’s Truvada among men and transgender women who have sex with men. Now, a second trial suggests that the superiority also holds true in women.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
